Scarica l'app Stockscreener
219.68
2.52%
-5.69
Dopo l'orario di chiusura:
219.60
-0.08
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$225.37
Aprire:
$226.89
Volume 24 ore:
5.67M
Relative Volume:
0.86
Capitalizzazione di mercato:
$388.43B
Reddito:
$61.16B
Utile/perdita netta:
$4.19B
Rapporto P/E:
93.03
EPS:
2.3614
Flusso di cassa netto:
$17.82B
1 W Prestazione:
-4.53%
1M Prestazione:
-5.11%
6M Prestazione:
+0.61%
1 anno Prestazione:
+3.84%
Intervallo 1D:
$219.44
$228.62
Intervallo di 1 settimana:
$219.44
$231.26
Portata 52W:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
Bimzelx Trial Win Raises New Questions For AbbVie Skyrizi Outlook - simplywall.st
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is AbbVie Inc. (ABBV) one of the debt free halal stocks to buy? - MSN
Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy? - Insider Monkey
Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities - The Motley Fool
AbbVie Inc Stock (ISIN: US00287Y1091) Faces Pressure Amid Valuation Concerns and Dividend Appeal - AD HOC NEWS
Revenue per share of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV - TradingView
AbbVie CEO’s pay jumped 75% to $32.5M in second year at the helm - Crain's Chicago Business
AbbVie Stock: Is This Pharma Giant Still a Buy-or-Bail in 2026? - AD HOC NEWS
AbbVie Inc. $ABBV Shares Sold by Van ECK Associates Corp - MarketBeat
Douglass Winthrop Advisors LLC Buys 9,022 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Holdings Cut by Bokf Na - MarketBeat
RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages - Insider Monkey
Antiviral Drugs Market Is Going to Boom Rapidly| AbbVie Inc., GSK plc, and Dr. Reddy's Laboratories Ltd. - openPR.com
AbbVie Reports Promising Results from Phase 1 Study of ABBV-295 - Insider Monkey
How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks - Yahoo Finance
AbbVie’s ABBV-295 Obesity Data Sparks Fresh Interest In Valuation - simplywall.st
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial - GuruFocus
AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis - Seeking Alpha
SageView Advisory Group LLC Buys 13,883 Shares of AbbVie Inc. $ABBV - MarketBeat
Kepler Cheuvreux Suisse SA Takes $7.54 Million Position in AbbVie Inc. $ABBV - MarketBeat
Mackenzie Financial Corp Sells 99,604 Shares of AbbVie Inc. $ABBV - MarketBeat
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV) - The Globe and Mail
Franklin Resources Inc. Trims Holdings in AbbVie Inc. $ABBV - MarketBeat
Capital World Investors Sells 139,297 Shares of AbbVie Inc. $ABBV - MarketBeat
ABBV Stock Price and Chart — NYSE:ABBV - TradingView
AbbVie Inc. (ABBV) gets downgraded to peer perform from outperform by Wolfe Research - MSN
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial - TechStock²
AbbVie Forecasts High Single-Digit Growth Through 2030 - National Today
AbbVie’s GLP-1 challenger posts strong weight-loss results in early trial - Crain's Chicago Business
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
AbbVie Posts Encouraging Early-Stage Data For Amylin Analog ABBV-295 - Citeline News & Insights
Richard Bernstein Advisors LLC Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Capital Research Global Investors Sells 34,749 Shares of AbbVie Inc. $ABBV - MarketBeat
Capital International Investors Has $2.48 Billion Stake in AbbVie Inc. $ABBV - MarketBeat
Capital International Inc. CA Has $55.65 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Legal & General Group Plc Has $2.78 Billion Holdings in AbbVie Inc. $ABBV - MarketBeat
Bank of Montreal Can Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
William Blair and BMO Maintain Outperform on AbbVie Inc. (ABBV) March 2026 - Meyka
AbbVie reports ‘positive’ results from Phase 1 study of ABBV-295 - TipRanks
AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 millionSEC filing - marketscreener.com
AbbVie (NYSE:ABBV) Shares Down 1% Following Insider Selling - MarketBeat
ICER to review AbbVie’s Parkinson’s disease drug - The Pharma Letter
AbbVie (ABBV) Reports Promising Phase 1 Results for Obesity Trea - GuruFocus
AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss - Benzinga
AbbVie sees promising early-stage data for weight loss asset ABBV-295 - Seeking Alpha
AbbVie Trial Updates Add Context To Valuation And Growth Outlook - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sienna Gestion Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Reports Promising Results from Phase 1 Study of AB - GuruFocus
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):